Minerva Surgical (UTRS) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock UTRS vs. NMRD, MOTS, VIVE, DRTSW, ANZUW, ATAKW, BBLGW, BRSHW, CTCXW, and CRGTShould you be buying Minerva Surgical stock or one of its competitors? The main competitors of Minerva Surgical include Nemaura Medical (NMRD), Motus GI (MOTS), Viveve Medical (VIVE), Alpha Tau Medical (DRTSW), Anzu Special Acquisition Corp I (ANZUW), Aurora Technology Acquisition (ATAKW), Bone Biologics (BBLGW), Bruush Oral Care (BRSHW), Carmell (CTCXW), and Cortigent (CRGT). These companies are all part of the "medical equipment" industry. Minerva Surgical vs. Its Competitors Nemaura Medical Motus GI Viveve Medical Alpha Tau Medical Anzu Special Acquisition Corp I Aurora Technology Acquisition Bone Biologics Bruush Oral Care Carmell Cortigent Nemaura Medical (NASDAQ:NMRD) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Is NMRD or UTRS more profitable? Company Net Margins Return on Equity Return on Assets Nemaura MedicalN/A N/A N/A Minerva Surgical N/A N/A N/A Which has more risk and volatility, NMRD or UTRS? Nemaura Medical has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Minerva Surgical has a beta of 3.67, indicating that its share price is 267% more volatile than the S&P 500. Does the media favor NMRD or UTRS? In the previous week, Nemaura Medical's average media sentiment score of 0.00 equaled Minerva Surgical'saverage media sentiment score. Company Overall Sentiment Nemaura Medical Neutral Minerva Surgical Neutral Do insiders & institutionals believe in NMRD or UTRS? 4.4% of Nemaura Medical shares are owned by institutional investors. 40.4% of Nemaura Medical shares are owned by insiders. Comparatively, 8.5% of Minerva Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, NMRD or UTRS? Nemaura Medical has higher earnings, but lower revenue than Minerva Surgical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNemaura Medical$3.02K0.00-$14.14M-$0.39N/AMinerva Surgical$51.69M0.00-$34.11MN/AN/A SummaryNemaura Medical beats Minerva Surgical on 3 of the 5 factors compared between the two stocks. Get Minerva Surgical News Delivered to You Automatically Sign up to receive the latest news and ratings for UTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTRS vs. The Competition Export to ExcelMetricMinerva SurgicalSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$256.84M$5.55B$9.04BDividend YieldN/AN/A5.22%4.00%P/E RatioN/A5.9227.6420.24Price / SalesN/A73.84417.15117.30Price / CashN/A196.1236.8958.10Price / BookN/A6.338.035.67Net Income-$34.11M-$27.18M$3.18B$249.21M Minerva Surgical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTRSMinerva SurgicalN/AN/AN/AN/A$1K$51.69M0.00160NMRDNemaura Medical1.0005 of 5 stars$0.00flatN/AN/A$4K$3.02K0.0040MOTSMotus GI0.0713 of 5 stars$0.00flatN/AN/A$2K$319K0.0030VIVEViveve MedicalN/A$0.00-90.0%N/AN/A$1K$6.83M0.0070DRTSWAlpha Tau MedicalN/A$0.24-3.7%N/A+5.5%$0.00N/A0.0080News CoveragePositive NewsANZUWAnzu Special Acquisition Corp IN/A$0.04+16.4%N/A+1.2%$0.00N/A0.002Gap UpATAKWAurora Technology AcquisitionN/A$0.01-16.7%N/A-53.9%$0.00N/A0.00N/AGap DownBBLGWBone BiologicsN/A$15.00+11.1%N/A-65.5%$0.00N/A0.002Gap UpBRSHWBruush Oral CareN/AN/AN/AN/A$0.00$2.92M0.0011CTCXWCarmellN/A$0.03+6.8%N/A-63.2%$0.00$32.84K0.0014Gap UpCRGTCortigentN/AN/AN/AN/A$0.00N/A0.006High Trading Volume Related Companies and Tools Related Companies Nemaura Medical Alternatives Motus GI Alternatives Viveve Medical Alternatives Alpha Tau Medical Alternatives Anzu Special Acquisition Corp I Alternatives Aurora Technology Acquisition Alternatives Bone Biologics Alternatives Bruush Oral Care Alternatives Carmell Alternatives Cortigent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTRS) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Surgical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Surgical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
